NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

AXL激酶抑制劑:流行病學考察 (∼2030年)

AXL Kinase Inhibitors - Epidemiology Insight - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966756
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
AXL激酶抑制劑:流行病學考察 (∼2030年) AXL Kinase Inhibitors - Epidemiology Insight - 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供美國,歐洲5國(德國,西班牙,義大利,法國,英國)以及日本等7個主要市場AXL激酶抑制劑市場詳細說明,提供疾病的背景和概要,未滿足需求,各國的流行病學,治療方法等相關資訊。

目錄

第1章 主要考察

第2章 摘要整理

第3章 AXL激酶抑制劑:疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第4章 患者治療過程

第5章 流行病學和患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 主要7個國家的AXL激酶抑制劑的流行病學方案
  • 美國的流行病學
    • 美國的AXL激酶抑制劑的流行病學方案
  • 歐洲5國的流行病學:各國
    • 德國的流行病學
    • 法國的流行病學
    • 義大利的流行病學
    • 西班牙的流行病學
    • 英國的流行病學
  • 日本的流行病學
    • 日本的AXL激酶抑制劑的流行病學方案

第6章 治療流程,目前治療,及醫療行為

  • AXL激酶抑制劑的治療和管理
  • AXL激酶抑制劑的治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

  • 參考文獻
  • 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1031

DelveInsight's 'AXL Kinase Inhibitors - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted AXL Kinase Inhibitors epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

AXL Kinase Inhibitors Understanding

The DelveInsight AXL Kinase Inhibitors epidemiology report gives a thorough understanding of the AXL Kinase Inhibitors by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for AXL Kinase Inhibitors in the US, Europe, and Japan. The report covers the detailed information of the AXL Kinase Inhibitors epidemiology scenario in seven major countries (US, EU5, and Japan).

AXL Kinase Inhibitors Epidemiology Perspective by DelveInsight

The AXL Kinase Inhibitors epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The AXL Kinase Inhibitors epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The AXL Kinase Inhibitors epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

AXL Kinase Inhibitors Detailed Epidemiology Segmentation

The AXL Kinase Inhibitors epidemiology covered in the report provides historical as well as forecasted AXL Kinase Inhibitors epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight AXL Kinase Inhibitors report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The AXL Kinase Inhibitors report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The AXL Kinase Inhibitors Epidemiology Report and Model provide an overview of the risk factors and global trends of AXL Kinase Inhibitors in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of AXL Kinase Inhibitors in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of AXL Kinase Inhibitors
  • The report provides the segmentation of the AXL Kinase Inhibitors epidemiology

Report Highlights:

  • 11-Year Forecast of AXL Kinase Inhibitors epidemiology
  • 7MM Coverage
  • Total Cases of AXL Kinase Inhibitors
  • Total Cases of AXL Kinase Inhibitors according to segmentation
  • Diagnosed cases of AXL Kinase Inhibitors

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to AXL Kinase Inhibitors?
  • What are the key findings pertaining to the AXL Kinase Inhibitors epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of AXL Kinase Inhibitors across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the AXL Kinase Inhibitors?
  • What are the currently available treatments of AXL Kinase Inhibitors?

Reasons to buy:

  • The AXL Kinase Inhibitors Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global AXL Kinase Inhibitors market
  • Quantify patient populations in the global AXL Kinase Inhibitors market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AXL Kinase Inhibitors therapeutics in each of the markets covered
  • Understand the magnitude of AXL Kinase Inhibitors population by its epidemiology
  • The AXL Kinase Inhibitors Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of AXL Kinase Inhibitors

3. AXL Kinase Inhibitors : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. AXL Kinase Inhibitors Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. AXL Kinase Inhibitors Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. AXL Kinase Inhibitors Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. AXL Kinase Inhibitors Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. AXL Kinase Inhibitors Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. AXL Kinase Inhibitors Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. AXL Kinase Inhibitors Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. AXL Kinase Inhibitors Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. AXL Kinase Inhibitors Treatment and Management
  • 6.2. AXL Kinase Inhibitors Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: AXL Kinase Inhibitors Epidemiology in 7MM (2017-2030)
  • Table 2: AXL Kinase Inhibitors Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: AXL Kinase Inhibitors Epidemiology in the United States (2017-2030)
  • Table 4: AXL Kinase Inhibitors Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: AXL Kinase Inhibitors Epidemiology in Germany (2017-2030)
  • Table 6: AXL Kinase Inhibitors Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: AXL Kinase Inhibitors Epidemiology in France (2017-2030)
  • Table 8: AXL Kinase Inhibitors Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: AXL Kinase Inhibitors Epidemiology in Italy (2017-2030)
  • Table 10: AXL Kinase Inhibitors Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: AXL Kinase Inhibitors Epidemiology in Spain (2017-2030)
  • Table 12: AXL Kinase Inhibitors Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: AXL Kinase Inhibitors Epidemiology in the United Kingdom (2017-2030)
  • Table 14: AXL Kinase Inhibitors Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: AXL Kinase Inhibitors Epidemiology in Japan (2017-2030)
  • Table 16: AXL Kinase Inhibitors Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: AXL Kinase Inhibitors Epidemiology in 7MM (2017-2030)
  • Figure 2: AXL Kinase Inhibitors Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: AXL Kinase Inhibitors Epidemiology in the United States (2017-2030)
  • Figure 4: AXL Kinase Inhibitors Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: AXL Kinase Inhibitors Epidemiology in Germany (2017-2030)
  • Figure 6: AXL Kinase Inhibitors Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: AXL Kinase Inhibitors Epidemiology in France (2017-2030)
  • Figure 8: AXL Kinase Inhibitors Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: AXL Kinase Inhibitors Epidemiology in Italy (2017-2030)
  • Figure 10: AXL Kinase Inhibitors Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: AXL Kinase Inhibitors Epidemiology in Spain (2017-2030)
  • Figure 12: AXL Kinase Inhibitors Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: AXL Kinase Inhibitors Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: AXL Kinase Inhibitors Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: AXL Kinase Inhibitors Epidemiology in Japan (2017-2030)
  • Figure 16: AXL Kinase Inhibitors Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report